Becton, Dickinson and Company Introduces Specialized Syringe For Eli Lilly's Highly Concentrated Insulin
Becton, Dickinson and Company (BD) has launched a new syringe designed specifically for diabetic patients taking Humulin R U-500, concentrated insulin developed and manufactured by Eli Lilly. By using a specialized syringe, patients and clinicians can avoid the dosing errors associated with traditional insulin syringes.
Some diabetic patients become resistant to insulin therapy and require higher doses — 200 units per day — to manage their disease correctly. Eli Lilly’s Humulin R U-500 contains five times more insulin per milliliter than traditional U-100 insulin, and has been available since 1994.
Some diabetic patients become resistant to insulin therapy and require higher doses — 200 units per day — to manage their disease correctly. Eli Lilly’s Humulin R U-500 contains five times more insulin per milliliter than traditional U-100 insulin, and has been available since 1994.